ADVFN - ニュース

S&P 500

5,267.84

-0.74%

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

銘柄名/コード:

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/24	06 : 06	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BECN	Beacon Roofing Supply Inc
2024/05/24	06 : 05	Edgar (US Regulatory)	Form SD - Specialized disclosure report	NYSE:HBI	Hanesbrands Inc
2024/05/24	06 : 05	Edgar (US Regulatory)	Form DEFR14A - Revised definitive proxy soliciting materials	NASDAQ:NCNO	nCino Inc
2024/05/24	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:CRM	Salesforce Inc
2024/05/24	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PODD	Insulet Corporation
2024/05/24	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PRVA	Privia Health Group Inc
2024/05/24	06 : 05	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:TCPC	BlackRock TCP Capital Corporation
2024/05/24	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HOOK	HOOKIPA Pharma Inc
2024/05/24	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CADL	Candel Therapeutics Inc
2024/05/24	06 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EVAX	Evaxion Biotech AS
2024/05/24	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PRVA	Privia Health Group Inc
2024/05/24	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XEL	Xcel Energy Inc
2024/05/24	06 : 05	Business Wire	Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
2024/05/24	06 : 05	GlobeNewswire Inc.	Elcora Announces Share Consolidation	TSXV:ERA	Elcora Advanced Materials Corp
2024/05/24	06 : 05	GlobeNewswire Inc.	Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024	NASDAQ:AFMD	Affimed NV
2024/05/24	06 : 05	Business Wire	Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms	NYSE:BMY	Bristol Myers Squibb Co
2024/05/24	06 : 05	PR Newswire (US)	EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting
2024/05/24	06 : 05	PR Newswire (US)	Landmark Study from Mercy BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and Ultrasound for Ovarian Cancer Screening
2024/05/24	06 : 05	PR Newswire (US)	IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma	NASDAQ:IDYA	IDEAYA Biosciences Inc
2024/05/24	06 : 05	PR Newswire (US)	ALIMENTATION COUCHE-TARD TO RELEASE RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR 2024 ON JUNE 25, 2024	TSX:ATD	Alimentation Couche Tard Inc
2024/05/24	06 : 05	PR Newswire (Canada)	ALIMENTATION COUCHE-TARD TO RELEASE RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR 2024 ON JUNE 25, 2024	TSX:ATD	Alimentation Couche Tard Inc
2024/05/24	06 : 05	GlobeNewswire Inc.	FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology	NASDAQ:FGEN	FibroGen Inc
2024/05/24	06 : 05	PR Newswire (Canada)	ALIMENTATION COUCHE-TARD DIFFUSERA LE 25 JUIN PROCHAIN LES RÉSULTATS DE SON QUATRIÈME TRIMESTRE ET DE SON EXERCICE 2024	TSX:ATD	Alimentation Couche Tard Inc
2024/05/24	06 : 05	Business Wire	TelevisaUnivision Announces Pricing of $1.0 Billion Debt
2024/05/24	06 : 05	GlobeNewswire Inc.	Elcora Announces Share Consolidation	ELM
2024/05/24	06 : 05	GlobeNewswire Inc.	Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meet	NASDAQ:CMPX	Compass Therapeutics Inc
2024/05/24	06 : 05	GlobeNewswire Inc.	Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer	NASDAQ:COGT	Cogent Biosciences Inc
2024/05/24	06 : 05	Business Wire	Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting	NASDAQ:BCYC	Bicycle Therapeutics PLC
2024/05/24	06 : 05	GlobeNewswire Inc.	I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024	NASDAQ:IMAB	I MAB
2024/05/24	06 : 05	PR Newswire (US)	Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting	NASDAQ:BPMC	Blueprint Medicines Corporation